Dr. Samip R. Master - Hematology ...

Dr. Samip Master

Claim this profile

LSU Health Sciences Center at Shreveport

Studies Multiple Myeloma
Studies Melanoma
5 reported clinical trials
13 drugs studied

Area of expertise

1Multiple Myeloma
Samip Master has run 2 trials for Multiple Myeloma. Some of their research focus areas include:
Stage I
Stage II
Stage III
2Melanoma
Samip Master has run 1 trial for Melanoma. Some of their research focus areas include:
Stage IV
Stage III
BRAF positive

Affiliated Hospitals

Image of trial facility.
LSU Health Sciences Center At Shreveport
Image of trial facility.
Ochsner LSU Health Monroe Medical Center

Clinical Trials Samip Master is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Image of trial facility.

Nivolumab + Ipilimumab + Sargramostim

for Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria

More about Samip Master

Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Samip Master has experience with
  • Ipilimumab
  • Nivolumab
  • Dexamethasone
  • Lenalidomide
  • Sargramostim
  • Bortezomib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Samip Master specialize in?
Is Samip Master currently recruiting for clinical trials?
Are there any treatments that Samip Master has studied deeply?
What is the best way to schedule an appointment with Samip Master?
What is the office address of Samip Master?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security